Skip to content

Surgical Treatment of Concurrent Cataract and Primary Pterygium

Surgical Treatment of Concurrent Cataract and Primary Pterygium: A Randomized Control Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00563277
Enrollment
75
Registered
2007-11-26
Start date
2004-10-31
Completion date
2006-12-31
Last updated
2010-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Lenses, Intraocular, Pterygium

Keywords

Pterygium, Cataract, Intraocular lens power calculation accuracy

Brief summary

Pterygium is known to induce with-the-rule astigmatism. The corneal curvature along the long axis of the pterygium body is flattened. The excision of pterygium will result in steepening of the cornea and reduction of astigmatism. Therefore, the effect of pterygium excision on intraocular lens (IOL) power calculation has been examined in our previous study. The study confirmed that pterygium can cause alteration of IOL power. The determination of IOL power for cataract surgery is usually calculated from IOL formula called SRK II formula. IOL power = A - (2.5 x AL)-(0.9 x K). Variable A denotes the A-constant of the intraocular lens which is dependent on the IOL material and refractive index. Other variables for input include axial length (AL) and keratometry (K). A larger K reading will result in a lower estimated IOL power and vice versa. Previous studies have documented simultaneous cataract and pterygium operation resulted in reasonable visual outcome without adjustment of IOL power. With the presence of a pterygium, the cornea is flattened and lead to a reduction of K value and over-estimation of calculated IOL power. This randomized controlled trial is designed to compare the refractive outcomes of sequential and simultaneous pterygium and cataract operation. Pterygium excision should be done with various adjuvant therapies to minimize recurrence. Our previous studies reliably demonstrated limbal conjunctival graft and mitomycin C were effective methods to achieve low pterygium recurrence. We use limbal conjunctival autograft as the adjuvant therapy in the current study because this method is safer to be performed either alone or in combination with phacoemulsification. We avoid using mitomycin C as the adjuvant therapy in order to minimize the possibility of intraocular toxicity due to seepage.

Interventions

PROCEDUREcombined pterygium and cataract operation
PROCEDUREpterygium excision followed by cataract operation

Sponsors

Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* \>18 years old * Primary pterygium \> 2mm across corneal limbus \[Measurement made from the imaginary line of surgical limbus to the most advance edge of the visible pterygium tissue\] Concurrent visually significant cataract ( BCVA \< 20/70 ) * Informed consent for both pterygium and cataract surgery

Exclusion criteria

* Temporal pterygium * Double headed pterygium * Previous ocular surgery in which conjunctival-limbal graft is not feasible * Pterygium covering visual axis that preclude keratometric assessment * History of scleritis or autoimmune diseases

Design outcomes

Primary

MeasureTime frame
final refraction deviation from target1 and 3 months post cataract operation

Secondary

MeasureTime frame
change of IOL power from pre-pterygium estimated power1 and 3 months post pterygium excision

Countries

China

Contacts

Primary ContactLulu Cheng, Dr
chenglu@i-cable.com(852) 2632 2878

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026